Changes in Demographic and Clinical Characteristics of MuSK Myasthenia Gravis
European Journal of Neurology · 2026-11 · 33 (11)
DOI: 10.1111/ene.70785 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 30.10.2026. Verfasst von Silvia Falso und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Cholinergic, Receptor Protein-Tyrosine Kinases. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Over the last two decades, an increasing number of late‐ and very‐late onset myasthenia gravis cases (VLOMG) with acetylcholine receptor antibodies (AChR‐MG) have been reported, whereas demographic studies on muscle‐specific tyrosine kinase antibodies MG (MuSK‐MG) are lacking. We investigated whether the proportion of patients with MuSK‐MG with onset ≥ 50 years has increased and whether these patients show distinct clinical characteristics.
Methods
We retrospectively enrolled consecutive patients with MuSK‐MG onset ≥ 16 years followed between 1980 and 2025 at our tertiary center. Demographic characteristics and maximum disease severity, classified according to Myasthenia Gravis Foundation of America classification, were analyzed. Patients were stratified into three age‐at‐onset subgroups.
Results
Overall, 120 patients were included. A significant increase in the median age at MuSK‐MG onset was observed, from 36 years (IQR, 23–45.75) in the 1980s to 47 years (IQR, 29–69) in the 2013–2025 period ( p = 0.033). Patients with onset ≥ 50 years increased from 2/17 (11.8%) to 19/39 (48.7%) ( p = 0.015), including 12 VLOMG cases. Males increased from 23.5% to 35.9%. Maximum MG severity decreased over time, with a remarkable reduction of respiratory crises ( p = 0.004), with no significant differences across age‐at‐onset groups.
Conclusions
Demographic changes observed in AChR‐MG also occur, though less prominently, in MuSK‐MG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
- Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
ORCID-Profile: Silvia Falso, Sofia Marini, Federico Habetswallner, Amelia Evoli, Raffaele Iorio
Zitieren
APA
Falso, S., Marini, S., Marini, M., Habetswallner, F., Evoli, A., & Iorio, R. (2026). Changes in Demographic and Clinical Characteristics of MuSK Myasthenia Gravis. European Journal of Neurology, 33(11). https://doi.org/10.1111/ene.70785
Vancouver
Falso S, Marini S, Marini M, Habetswallner F, Evoli A, Iorio R. Changes in Demographic and Clinical Characteristics of MuSK Myasthenia Gravis. European Journal of Neurology. 2026;33(11). doi:10.1111/ene.70785
BibTeX
@article{Falso2026,
author = {Falso, Silvia and Marini, Sofia and Marini, Martina and Habetswallner, Federico and Evoli, Amelia and Iorio, Raffaele},
title = {Changes in Demographic and Clinical Characteristics of MuSK Myasthenia Gravis},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/ene.70785}
}
EUVIMED